{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3"},{"groupId":"OG001","value":"92.3"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"100.0"}]}],"title":"Cycle 5 Day 1 (n=15,1319,1,2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"Cycle 6 Day 1(n= 15,14,18,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 28 Day Visit (n=15,11,19,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 56 Day Visit (n=15,9,15,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 3 Month Visit (n=16,8,18,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7"},{"groupId":"OG001","value":"92.3"},{"groupId":"OG002","value":"94.1"},{"groupId":"OG003","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 6 Month Visit (n=15,13,17,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3"},{"groupId":"OG001","value":"84.6"},{"groupId":"OG002","value":"60.0"},{"groupId":"OG003","value":"100.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 9 Month Visit (n=15,13,15,1,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"85.7"},{"groupId":"OG002","value":"45.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 12 Month Visit (n=14,14,20,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"54.5"},{"groupId":"OG002","value":"40.0"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 15 Month Visit (n=14,11,15,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"26.7"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 18 Month Visit (n=13,14,15,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"18.8"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 21 Month Visit (n=13,12,16,0,0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"21.4"},{"groupId":"OG002","value":"18.8"},{"comment":"No participants were analyzed in this group.","groupId":"OG003","value":"NA"},{"comment":"No participants were analyzed in this group.","groupId":"OG004","value":"NA"}]}],"title":"FU 24 Month Visit (n=12,14,16,0,0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.","groups":[{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1400 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 1: Rituximab SC 1400 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1600 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 1: Rituximab SC 1600 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1870 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG002","title":"Part 1: Rituximab SC 1870 mg"},{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1000 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG003","title":"Rituximab SC 1000 mg"},{"description":"These participants were withdrawn prior to SC treatment.","id":"OG004","title":"Part 1: No SC Dose Received"}],"paramType":"NUMBER","populationDescription":"Part 1 SAP; n = number of participants analyzed at the specified visit.","reportingStatus":"POSTED","timeFrame":"Day 1 pre-dose of Cycles 5 and 6 and Follow-up Days 28 and 56 and Follow-up Visits at Months 3, 6, 9, 12, 15, 18, 21 and 24","title":"Part 1: Percentage of Participants With Total B-Cell Depletion by Visit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}